Maxitarg-A Novel Targeting Approach for Hepatic Cancer


Keywords: , ,

The efficacy of current cancer chemotherapy is mainly limited by toxicity associated with the systemic spread of anticancer drugs to normal tissues. Enhancing selectivity or maximizing targeting towards cancer cells would be important approach to decrease toxicity while enhancing efficacy. The present approach, ‘MAXITARG’ to maximize the targeting of drugs deals with the use of a novel-targeting agent with high affinity for hepatocellular carcinoma cells. Doxorubicin is widely used for various solid tumors and melanomas including hepatocellular carcinoma. Limitations of doxorubicin delivery include dose limited cardiotoxicity and myelosuppression. The result of this is often a narrow therapeutic index, due to high levels of toxicity to healthy tissues. ‘MAXITARG’ deals with the use of alginic acid-sodium alginate nanoparticles (ANP) with the novel-targeting agent for the therapy of hepatic cancer. The aim of the present study is to use the ‘MAXITARG’ approach to maximize delivery of doxorubicin to hepatic carcinoma cells. The results suggested the promise of developed ‘MAXITARG’ as a suitable approach for hepatic cancer. The technology could be extrapolated to other category of drugs for liver targeting.

PDF of paper:

Journal: TechConnect Briefs
Volume: 1, Technical Proceedings of the 2005 NSTI Nanotechnology Conference and Trade Show, Volume 1
Published: May 8, 2005
Pages: 11 - 14
Industry sectors: Advanced Materials & Manufacturing | Medical & Biotech
Topics: Biomaterials, Cancer Nanotechnology
ISBN: 0-9767985-0-6